We are live on ! Find out more
TECP

Trails Edge Capital Partners Portfolio holdings

AUM $630M
This Fund
S&P 500
This Quarter Est. Return
+17.35%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$437M
AUM Growth
+$31.8M
Cap. Flow
+$10.1M
Cap. Flow %
2.32%
Top 10 Hldgs %
62.79%
Holding
35
New
12
Increased
4
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$28.4M
2
RVMD icon
Revolution Medicines
RVMD
+$24.7M
3
CYTK icon
Cytokinetics
CYTK
+$19.1M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$15.2M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$11.3M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$37.9M
2
TYRA icon
Tyra Biosciences
TYRA
+$18.4M
3
FOLD
Amicus Therapeutics
FOLD
+$14.9M
4
APGE icon
Apogee Therapeutics
APGE
+$14.5M
5
DFTX
Definium Therapeutics
DFTX
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FTH
26
Faeth Therapeutics
FTH
$836M
$3.94M 0.9%
+125,000
New +$2.5M
IRD
27
Opus Genetics
IRD
$300M
$2.27M 0.52%
+500,000
New +$1.73M
ACAD icon
28
Acadia Pharmaceuticals
ACAD
$4.87B
– –
-1,419,406
Closed -$37.9M
APGE icon
29
Apogee Therapeutics
APGE
$10.2B
– –
-192,000
Closed -$14.5M
CMPX icon
30
Compass Therapeutics
CMPX
$405M
– –
-1,415,273
Closed -$7.6M
ELVN icon
31
Enliven Therapeutics
ELVN
$4.31B
– –
-199,306
Closed -$3.07M
FOLD
32
DELISTED
Amicus Therapeutics
FOLD
– –
-1,043,313
Closed -$14.9M
TERN
33
DELISTED
Terns Pharmaceuticals
TERN
– –
-300,000
Closed -$12.1M
TYRA icon
34
Tyra Biosciences
TYRA
$1.51B
– –
-700,000
Closed -$18.4M
MBX
35
MBX Biosciences
MBX
$3.3B
– –
-315,158
Closed -$9.94M
1
2

Similar funds

SJIC
St. James Investment Company Southlake, Texas $630M AUM 12.48% 1-Year Est. Return
SFO
Stenger Family Office Naperville, Illinois $629M AUM 25.67% 1-Year Est. Return
PPC
Park Place Capital Homewood, Alabama $629M AUM 18.27% 1-Year Est. Return
ACGA
Atlanta Consulting Group Advisors Atlanta, Georgia $631M AUM 22.46% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
MC
Machina Capital Paris, France $631M AUM 11.37% 1-Year Est. Return
GPTE
Generali Powszechne Towarzystwo Emerytalne Warsaw, Poland $631M AUM 32.98% 1-Year Est. Return
KNW
Kesler Norman & Wride Ogden, Utah $631M AUM 27.63% 1-Year Est. Return

Trails Edge Capital Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Trails Edge Capital Partners held 35 positions worth $437M, up 7.9% from $405M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Trails Edge Capital Partners's Q1 2026 filing shows 12 new, 4 increased, 7 reduced and 8 closed positions. Its largest new stake was Revolution Medicines: 245,000 shares worth $23.8M. The largest sale was Acadia Pharmaceuticals, an estimated $37.9M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier.

  • Trails Edge Capital Partners's largest Q1 2026 buy was Revolution Medicines: 245,000 shares worth $23.8M.
  • Trails Edge Capital Partners added most to Mirum Pharmaceuticals in Q1 2026, an estimated $28.4M increase.
  • Trails Edge Capital Partners's biggest Q1 2026 reduction was Definium Therapeutics, cutting an estimated $14.1M.
  • Trails Edge Capital Partners fully exited Acadia Pharmaceuticals in Q1 2026, selling an estimated $37.9M.
  • Trails Edge Capital Partners's ten largest holdings make up 63% of its $437M portfolio in Q1 2026.
  • Trails Edge Capital Partners opened 12 new positions and closed 8 in Q1 2026.
  • Trails Edge Capital Partners's portfolio value rose 7.9% quarter-over-quarter to $437M.

Based on Trails Edge Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.